Determining the safety and efficacy of biotherapeutics is a key part of the drug development process. There is a need to develop assays that accurately and reliably detect and quantify immune ...

Since the mid-1980s, therapeutic monoclonal antibodies have become the fastest-growing class of therapeutics. This was due to the numerous pharmaceutical companies that were trying to find more drug ...

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/c39ddb/pk_assays_for_biot) has announced the addition of Future Science Ltd's ...

First in human (FIH) clinical trials of bispecific immunostimulatory antibodies commonly require a low starting dose based on a minimum anticipated biological effect level (MABEL) approach. To ...

As the use of immunoassays to discover, detect, and quantitate proteins from a variety of biological samples has greatly expanded, so have requirements for enhanced sensitivity, precision, reliability ...

insights from industryNatalie Strickland Global Head of Translational ScienceSynexa Life Sciences In this interview, News Medical speaks with Natalie Strickland, Global Head of Translational Science ...

To generate a polyclonal antibody against sarsasapogenin and to develop an indirect competitive enzyme-linked immunosorbent assay (IC-ELISA) method for the pharmacokinetic study of Sarsasapogenin in ...

A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to Clinic MELBOURNE, Australia, March 10, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc” ...

The Assay Focuses Its Inner Eye on Complex Biology, Through 3D Models, Reporter Genes, Ubiquitin Traps, and More If the eye is the lamp of the body, the assay is a searchlight that illuminates complex ...

Assessing the safety and efficacy of biotherapeutics is imperative during the drug development process. In particular, pharmacokinetic (PK) and anti-drug antibody (ADA) assays are conducted to study ...